The Role of Activated Dendritic Cells in Autoimmune Diseases

Introduction to Dendritic Cells and Autoimmunity

Dendritic cells (DCs) represent a crucial component of the mammalian immune system, functioning as professional antigen-presenting cells that bridge innate and adaptive immunity. To define dendritic cells precisely, they are bone marrow-derived leukocytes characterized by their distinctive dendritic morphology and exceptional capacity to initiate primary immune responses. These specialized cells constantly sample their microenvironment for pathogens and tissue damage, processing captured antigens and presenting them to T lymphocytes. Under normal physiological conditions, DCs maintain immune tolerance to self-antigens, thereby preventing autoimmune reactions. However, when this delicate balance is disrupted, DCs can become powerful instigators of autoimmune pathology.

The transition from protective immunity to autoimmune aggression frequently involves the aberrant activation of dendritic cells. activated dendritic cells undergo significant phenotypic and functional changes, including upregulated expression of major histocompatibility complex (MHC) molecules and costimulatory receptors such as CD80, CD86, and CD40. These modifications enhance their T cell-stimulatory capacity, potentially leading to the breakdown of self-tolerance. In autoimmune conditions, DCs may present self-antigens to autoreactive T cells that have escaped thymic deletion, thereby initiating and perpetuating autoimmune responses. The Hong Kong Institute of Allergy and Autoimmunity has reported that approximately 5-8% of the Hong Kong population suffers from various autoimmune disorders, with rheumatoid arthritis and systemic lupus erythematosus showing increasing incidence rates over the past decade.

The dual nature of dendritic cells in immunity—both protective and pathogenic—makes them fascinating therapeutic targets. Under steady-state conditions, immature DCs promote tolerance through various mechanisms, including T cell deletion, anergy induction, and regulatory T cell generation. However, upon encountering danger signals in autoimmune contexts, these cells mature into potent immunostimulatory entities. Understanding the precise molecular switches that determine whether DCs induce tolerance or immunity represents a major focus in autoimmunity research. Recent advances in single-cell technologies have revealed unprecedented heterogeneity within DC populations, with specific subsets demonstrating preferential involvement in different autoimmune conditions.

Mechanisms of DC Activation in Autoimmune Diseases

Genetic Predisposition and DC Function

Genetic factors significantly influence dendritic cell function and susceptibility to autoimmune diseases. Numerous genome-wide association studies have identified polymorphisms in genes regulating DC biology that correlate with autoimmune predisposition. For instance, variants in IRF5, IRF8, and TYK2—genes encoding transcription factors and signaling molecules crucial for DC development and activation—have been strongly associated with systemic lupus erythematosus, multiple sclerosis, and other autoimmune conditions. These genetic alterations can lower activation thresholds in DCs, making them more responsive to environmental triggers and more likely to initiate autoimmune responses.

In Hong Kong Chinese populations, specific HLA haplotypes demonstrate particularly strong associations with autoimmune diseases. The HLA-DRB1*15:01 allele shows a significant correlation with multiple sclerosis susceptibility, while HLA-DRB1*04:05 associates with rheumatoid arthritis. These HLA molecules present antigens to T cells, and their specific structural characteristics may facilitate the presentation of self-peptides. Additionally, polymorphisms in genes involved in nucleic acid sensing pathways, such as TREX1 and RNASEH2, can lead to accumulation of endogenous nucleic acids that potently activate dendritic cells through intracellular nucleic acid sensors.

Role of TLRs and Other PRRs in Autoimmune Activation

Toll-like receptors (TLRs) and other pattern recognition receptors (PRRs) represent critical mediators of dendritic cell activation in autoimmunity. Under physiological conditions, these receptors recognize pathogen-associated molecular patterns (PAMPs) to initiate protective immune responses. However, in autoimmune settings, they frequently respond to endogenous ligands known as damage-associated molecular patterns (DAMPs). TLR7 and TLR9, which localize to endosomal compartments and recognize nucleic acids, have been particularly implicated in systemic lupus erythematosus pathogenesis. These receptors can be activated by self-DNA and self-RNA contained in immune complexes, leading to production of type I interferons and other inflammatory mediators.

Beyond TLRs, other PRR families including NOD-like receptors (NLRs), RIG-I-like receptors (RLRs), and C-type lectin receptors (CLRs) contribute to DC activation in autoimmunity. NLRP3 inflammasome activation in DCs leads to caspase-1-dependent processing and secretion of proinflammatory cytokines IL-1β and IL-18. The RIG-I receptor can recognize endogenous RNA species, while certain CLRs such as Dectin-1 and DC-SIGN modulate TLR signaling and influence the balance between tolerance and immunity. The convergence of multiple PRR signaling pathways often creates synergistic effects that amplify autoimmune responses beyond physiological levels.

Molecular Mimicry and DC Activation

Molecular mimicry represents a well-established mechanism whereby foreign antigens sharing structural similarities with self-antigens trigger autoimmune responses through dendritic cell activation. When DCs encounter microbial epitopes that resemble self-components, they may activate cross-reactive T cells that subsequently recognize and attack host tissues. This phenomenon has been implicated in several autoimmune diseases, including rheumatic fever following streptococcal infection, Guillain-Barré syndrome after Campylobacter jejuni infection, and potentially in type 1 diabetes following enteroviral infections.

The efficiency of molecular mimicry in triggering autoimmunity depends on several factors, including the degree of sequence or structural similarity between foreign and self-antigens, the avidity of T cell receptors for peptide-MHC complexes, and the activation state of antigen-presenting dendritic cells. Epitope spreading represents an additional layer of complexity, whereby initial immune responses against a single cross-reactive epitope expand to include additional self-epitopes through the presentation of novel self-antigens by activated DCs during tissue damage. This phenomenon can establish and broaden autoimmune reactions over time.

Role of DAMPs in Chronic Inflammation

Damage-associated molecular patterns (DAMPs) are endogenous molecules released from stressed or damaged cells that activate innate immunity through pattern recognition receptors on dendritic cells and other immune cells. In autoimmune diseases, persistent tissue damage leads to continuous DAMP release, creating a self-perpetuating cycle of inflammation. Well-characterized DAMPs include high-mobility group box 1 (HMGB1), heat-shock proteins, uric acid crystals, S100 proteins, and extracellular ATP. These molecules signal through receptors such as TLR2, TLR4, RAGE, and P2X7, promoting dendritic cell maturation and cytokine production.

The role of DAMPs extends beyond initial immune activation to include the establishment of chronic inflammation. HMGB1, for instance, exists in different redox forms that exhibit distinct immunostimulatory properties. The disulfide form of HMGB1 preferentially activates TLR4 signaling, leading to NF-κB activation and proinflammatory cytokine production, while the fully reduced form interacts with CXCL12 to promote leukocyte recruitment. Additionally, DAMPs can form complexes with other molecules to enhance their immunostimulatory capacity. HMGB1-DNA complexes, for example, potently activate dendritic cells through simultaneous engagement of RAGE and TLR9, driving robust type I interferon production characteristic of lupus pathogenesis.

DC Subsets and Their Involvement in Specific Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)

In systemic lupus erythematosus, dendritic cells play central roles in breaking tolerance to nuclear antigens and driving the characteristic autoantibody production. Plasmacytoid dendritic cells (pDCs) are particularly implicated through their robust capacity to produce type I interferons in response to immune complexes containing self-nucleic acids. These interferons create a feed-forward loop that promotes further autoantibody production and dendritic cell activation. Conventional DCs (cDCs) in SLE patients show enhanced maturation status and increased ability to present self-antigens to autoreactive T cells. Additionally, abnormalities in DC development and homeostasis have been reported, with alterations in the relative proportions of different DC subsets in peripheral blood.

Hong Kong registry data indicates that SLE affects approximately 40-50 per 100,000 individuals in the region, with a female-to-male ratio of approximately 9:1. Disease manifestations vary considerably among patients, but renal involvement represents a major cause of morbidity and mortality. Renal biopsies from lupus nephritis patients typically show abundant dendritic cell infiltrates, particularly in areas of active inflammation. These renal DCs likely contribute to local T cell activation and tissue damage. Therapeutic approaches targeting DC function in SLE include hydroxychloroquine (which inhibits endosomal TLR signaling), corticosteroids, and emerging biologics that interfere with type I interferon signaling or DC-T cell interactions.

Rheumatoid Arthritis (RA)

Rheumatoid arthritis involves dendritic cells in both the initiation phase in lymphoid organs and the effector phase within inflamed joints. In genetically susceptible individuals, DCs likely present citrullinated peptides to autoreactive T cells, initiating immune responses against joint components. Within the synovium, activated DCs contribute to local inflammation by producing proinflammatory cytokines and presenting antigens to resident T cells. Distinct DC subsets populate the rheumatoid joint, including conventional DCs, inflammatory DCs, and plasmacytoid DCs, each contributing differently to disease pathogenesis.

According to the Hong Kong Society of Rheumatology, rheumatoid arthritis affects approximately 0.3-0.5% of the local population, with peak onset between 30-50 years of age. Synovial tissue from RA patients shows increased numbers of CD1c+ and CD141+ conventional DCs compared to healthy controls or osteoarthritis patients. These DCs exhibit enhanced expression of costimulatory molecules and produce TNF-α, IL-6, and IL-23, contributing to the inflammatory milieu. Inflammatory DCs derived from monocytes are particularly abundant in rheumatoid synovium and demonstrate a remarkable capacity to activate T helper 17 cells, a key pathogenic population in RA. The presence of ectopic lymphoid structures containing DC-T cell clusters further supports their role in local immune activation.

Multiple Sclerosis (MS)

Multiple sclerosis involves dendritic cells in both the peripheral activation of autoreactive T cells and their recruitment to the central nervous system. DCs in peripheral lymphoid organs likely present myelin antigens to autoreactive CD4+ T cells, which then differentiate into effector cells capable of crossing the blood-brain barrier. Within the CNS, resident microglia and infiltrating DCs can reactivate these T cells, perpetuating inflammation and demyelination. Specific DC subsets appear to have distinct roles in MS pathogenesis, with cDC1s potentially involved in cross-presentation to CD8+ T cells and cDC2s specializing in CD4+ T cell activation.

Hong Kong epidemiological data indicates a rising incidence of multiple sclerosis, though prevalence remains lower than in Western populations (approximately 1-2 per 100,000). This difference may reflect both genetic and environmental factors influencing DC function. Cerebrospinal fluid from MS patients contains increased numbers of DCs compared to controls, and these cells exhibit enhanced activation markers. During relapses, myeloid DC numbers increase in the blood, possibly reflecting recruitment to inflammatory sites. Experimental evidence suggests that DCs not only initiate neuroinflammation but may also contribute to regulatory processes, as certain DC subsets can induce tolerance to myelin antigens under specific conditions.

Type 1 Diabetes (T1D)

In type 1 diabetes, dendritic cells are implicated in the breakdown of tolerance to pancreatic islet antigens. Within pancreatic lymph nodes, DCs present peptides derived from insulin, glutamic acid decarboxylase (GAD65), and other β-cell proteins to autoreactive T cells. The activation status and functional properties of these DCs significantly influence whether tolerance or autoimmunity develops. In non-obese diabetic (NOD) mice, a spontaneous model of T1D, DCs display abnormalities from early life, including enhanced activation and altered cytokine production. Human studies have similarly identified DC abnormalities in T1D patients and at-risk individuals.

Hong Kong diabetes registry data indicates that while type 2 diabetes predominates, type 1 diabetes affects approximately 0.02% of the population, with incidence increasing by 2-3% annually. Pancreatic histology from recent-onset T1D patients shows insulitis characterized by infiltrating T cells, B cells, macrophages, and dendritic cells. These pancreatic DCs likely contribute to local antigen presentation and T cell activation. Interestingly, certain DC subsets may also play protective roles in T1D. Tolerogenic DCs expressing indoleamine 2,3-dioxygenase (IDO) or presenting antigens in the absence of costimulation can induce regulatory T cells that suppress autoimmune responses against β-cells.

The Inflammatory Cytokine Milieu Driven by Activated DCs

IL-12 and IFN-γ Production

Activated dendritic cells are major producers of interleukin-12 (IL-12), a heterodimeric cytokine composed of p35 and p40 subunits that promotes T helper 1 (Th1) differentiation and interferon-gamma (IFN-γ) production. In autoimmune contexts, IL-12 drives pathogenic Th1 responses against self-antigens. The IL-12/IFN-γ axis has been particularly implicated in organ-specific autoimmune diseases such as type 1 diabetes and multiple sclerosis, where Th1 cells targeting pancreatic islets or myelin components, respectively, mediate tissue damage. Dendritic cells producing IL-12 typically do so in response to microbial products or endogenous danger signals engaging pattern recognition receptors.

The regulation of IL-12 production involves complex signaling networks and feedback mechanisms. While initial IL-12 secretion promotes Th1 differentiation, subsequent IFN-γ production by T cells can further enhance DC IL-12 production, creating a positive feedback loop that amplifies autoimmune responses. Additionally, IL-12 synergizes with other cytokines such as IL-18 to enhance IFN-γ production by T cells and NK cells. Therapeutic targeting of the IL-12 pathway has shown efficacy in certain autoimmune conditions, with ustekinumab (anti-IL-12/23 p40 subunit) demonstrating benefit in psoriasis and psoriatic arthritis. However, the pleiotropic functions of IL-12 in protective immunity necessitate careful consideration of potential immunosuppressive side effects.

IL-23 and IL-17 Production

The IL-23/IL-17 axis has emerged as a critical pathway in autoimmune pathogenesis, with dendritic cells serving as important sources of IL-23. This cytokine, composed of p19 and p40 subunits, stabilizes and expands T helper 17 (Th17) cells, which produce IL-17A, IL-17F, IL-21, and IL-22. Th17 cells and their effector cytokines contribute to autoimmune tissue damage in diseases such as rheumatoid arthritis, psoriasis, and multiple sclerosis. IL-23 production by DCs is typically induced by combined signals through pattern recognition receptors and inflammatory cytokines, with different DC subsets exhibiting varying capacities for IL-23 production.

Inflammatory DCs derived from monocytes demonstrate particularly robust IL-23 production in response to various stimuli. The IL-23/IL-17 axis mediates autoimmune pathology through multiple mechanisms, including neutrophil recruitment, epithelial barrier disruption, and induction of additional inflammatory mediators. IL-23 also acts on innate lymphoid cells and γδ T cells to promote IL-17 production, expanding the cellular sources of this cytokine beyond conventional Th17 cells. Therapeutic targeting of this pathway has proven highly successful, with antibodies against IL-23p19 (guselkumab, risankizumab) and IL-17 (secukinumab, ixekizumab) showing remarkable efficacy in psoriasis and other Th17-mediated diseases.

TNF-α and IL-6 Production

Tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) represent two pivotal inflammatory cytokines produced by activated dendritic cells in autoimmune diseases. TNF-α exists in both membrane-bound and soluble forms and signals through TNFR1 and TNFR2 to activate NF-κB and MAPK pathways, driving expression of additional inflammatory mediators and adhesion molecules. In rheumatoid arthritis, TNF-α promotes synovial inflammation, cartilage degradation, and bone erosion. Dendritic cells contribute to TNF-α production both directly and indirectly through stimulation of other cell types.

IL-6 exhibits pleiotropic effects in immunity and inflammation, influencing T cell differentiation, B cell antibody production, acute phase response, and hematopoiesis. Dendritic cell-derived IL-6 promotes Th17 differentiation while inhibiting regulatory T cell development, thereby tilting the balance toward autoimmunity. Additionally, IL-6 trans-signaling through soluble IL-6R contributes to chronic inflammation and tissue damage. The therapeutic success of TNF inhibitors (infliximab, adalimumab, etanercept) and IL-6 receptor blockade (tocilizumab) in various autoimmune conditions underscores the importance of these cytokines in disease pathogenesis. However, not all patients respond adequately to these therapies, highlighting the complexity of cytokine networks in autoimmunity.

Therapeutic Strategies Targeting DC Activation in Autoimmunity

Blocking TLR Signaling

Inhibiting Toll-like receptor signaling represents a promising approach to dampen dendritic cell activation in autoimmune diseases. Several strategies have been developed to target specific TLR pathways implicated in autoimmunity. Antimalarial drugs such as hydroxychloroquine and chloroquine, widely used in systemic lupus erythematosus and rheumatoid arthritis, inhibit endosomal acidification and thereby interfere with TLR7 and TLR9 signaling. More specific approaches include oligonucleotide-based antagonists that compete with endogenous ligands for receptor binding, and small-molecule inhibitors targeting TLR intracellular signaling domains.

Clinical trials evaluating TLR inhibitors have yielded mixed results, reflecting the complexity of TLR functions in both protective immunity and autoimmunity. While global suppression of TLR signaling may increase infection risk, more targeted approaches aiming to restore balance without complete inhibition show promise. These include cell-specific targeting using antibody-drug conjugates and spatial-temporal control of inhibitor delivery to inflammatory sites. Additionally, combination therapies that simultaneously target multiple TLR pathways or TLR signaling in conjunction with other activation signals may provide enhanced efficacy while minimizing immunosuppression.

Inhibiting DC Migration

Preventing dendritic cell migration to lymphoid organs or inflammatory sites represents another therapeutic strategy to limit their autoimmune functions. Dendritic cell trafficking depends on chemokine receptors and adhesion molecules that can be targeted pharmacologically. The CCR7-CCL19/CCL21 axis is particularly important for DC migration to lymph nodes, while inflammatory chemokine receptors such as CCR2, CCR5, and CXCR3 mediate recruitment to peripheral tissues. Inhibitors of these receptors have shown efficacy in preclinical models of autoimmunity.

Fingolimod (FTY720), approved for multiple sclerosis treatment, acts as a functional antagonist of sphingosine-1-phosphate receptors and thereby traps lymphocytes in lymphoid organs. While its primary mechanism involves T cells, fingolimod also affects DC migration and function. Other migration inhibitors under investigation include antagonists of CCR2, CCR5, and CXCR3, which are expressed on activated DCs and T cells. The challenge in targeting migration lies in achieving sufficient specificity to avoid compromising protective immune responses. Tissue-specific targeting and temporary inhibition during disease flares represent potential solutions to this challenge.

Targeting Cytokine Production

Directly targeting cytokine production by activated dendritic cells offers a more specific approach to modulate autoimmune responses without completely suppressing DC functions. Multiple strategies exist to inhibit cytokine production or activity, including monoclonal antibodies against cytokines or their receptors, soluble cytokine receptors, and small molecules that interfere with cytokine signaling pathways. As discussed previously, inhibitors of TNF-α, IL-6, IL-12/23, and IL-17 have demonstrated clinical efficacy in various autoimmune conditions.

Emerging approaches focus on upstream regulation of cytokine production through targeting intracellular signaling pathways. Inhibitors of JAK kinases, which mediate signaling downstream of multiple cytokine receptors, have shown broad efficacy in autoimmune diseases. Tofacitinib (JAK1/3 inhibitor) and baricitinib (JAK1/2 inhibitor) are approved for rheumatoid arthritis treatment, while more selective JAK inhibitors are in development. Additionally, molecules that interfere with NF-κB signaling, MAPK pathways, or inflammasome activation can suppress DC cytokine production. The optimal therapeutic approach likely involves combination strategies that target multiple cytokines or cytokine pathways simultaneously.

Inducing Tolerogenic DCs

Perhaps the most elegant therapeutic approach involves reprogramming pathogenic dendritic cells into tolerogenic entities that actively suppress autoimmune responses. Tolerogenic DCs exhibit reduced expression of costimulatory molecules and produce anti-inflammatory cytokines such as IL-10 and TGF-β instead of proinflammatory mediators. These cells can induce T cell anergy, deletion, or conversion to regulatory T cells, thereby restoring immune tolerance. Multiple strategies exist to generate tolerogenic DCs, including pharmacological agents (vitamin D3, dexamethasone, rapamycin), biological agents (IL-10, TGF-β), and genetic modification.

Clinical trials of tolerogenic DC therapy in autoimmune diseases have shown promising results, with acceptable safety profiles and evidence of immunomodulatory effects. In type 1 diabetes, autologous DCs treated with antisense oligonucleotides targeting CD40, CD80, and CD86 have demonstrated safety and potential efficacy in preserving β-cell function. Similar approaches are being explored in rheumatoid arthritis, multiple sclerosis, and other conditions. The dendritic cell therapy success rate in early clinical trials has been encouraging, with approximately 60-70% of treated patients showing immunological or clinical improvement in phase I/II studies. However, challenges remain in optimizing DC generation protocols, determining optimal dosing and administration routes, and identifying patient populations most likely to benefit.

Understanding the Complex Role of DCs in Autoimmunity for Improved Therapies

The multifaceted functions of dendritic cells in autoimmune diseases present both challenges and opportunities for therapeutic development. As central regulators of immune responses, DCs integrate diverse signals from their microenvironment and determine subsequent adaptive immune outcomes. In autoimmunity, this delicate regulatory balance is disrupted, leading to inappropriate activation of self-reactive lymphocytes. A comprehensive understanding of DC biology in specific autoimmune contexts is essential for designing targeted therapies that restore immune homeostasis without compromising protective immunity.

Recent technological advances have dramatically enhanced our understanding of DC heterogeneity and function in human autoimmunity. Single-cell RNA sequencing has revealed previously unappreciated diversity within DC populations, with distinct subsets exhibiting specialized functions in different disease contexts. Spatial transcriptomics and multiplexed imaging techniques are elucidating how DCs interact with other immune and non-immune cells within diseased tissues. These insights are facilitating the development of more precise therapeutic strategies that target specific DC subsets or functions relevant to particular autoimmune conditions.

The future of DC-targeted therapies likely lies in combination approaches that simultaneously address multiple aspects of DC dysregulation in autoimmunity. These may include inhibiting pathogenic activation signals while promoting tolerogenic programs, targeting specific DC subsets in a spatiotemporally controlled manner, and personalizing therapies based on individual DC phenotypes and functional states. As our understanding of human DC biology continues to deepen, we can anticipate increasingly sophisticated and effective therapeutic strategies that harness the immunoregulatory potential of these remarkable cells to treat autoimmune diseases more effectively and with fewer side effects than current approaches.